@FierceBiotech: La Jolla dumps its NASH drug and shifts its focus to rare disease. Report | Follow @FierceBiotech
@JohnCFierce: My thought: FDA panels lean on the side of approval, especially for a disease like CF. Any ??? can be answered post approval. $VRTX wins. | Follow @JohnCFierce
> Amgen ($AMGN) has successfully blocked Novartis ($NVS) from launching its Neupogen biosimilar in the U.S., at least for now. Story
> The FDA lifted its clinical hold on NeuroDerm's ($NDRM) Parkinson's disease treatments, allowing the biotech to get its development program back on track. More
> So-called safety switches could help the developers of CAR-T treatments make their cell therapies more tolerable. Feature
Medical Device News
@FierceMedDev: Adaptive Biotechnologies reels in $195M for immunosequencing tech. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Smith & Nephew boosts rep-less sales pilot by acquiring software assets that help automate training. Article | Follow @VarunSaxena2
@EmilyWFierce: ICYMI: RainDance shoots for long reads of whole genome with Pac Bio collaboration. Item | Follow @EmilyWFierce
> Mayo Clinic study finds digital health interventions reduce risk of cardiovascular disease. More
> Fitbit files for up to $100M IPO as it dominates fitness wearables and aims for corporate wellness. Story
> Smartphone-based diagnostic device detects parasitic worms via video. News
Pharma News
@FiercePharma: Japan's Eisai makes moves for Indian API manufacturing in further cost trimming. FiercePharmaAsia story | Follow @FiercePharma
@CarlyHFierce: ICYMI: Valeant chief Pearson the next Warren Buffett? Deal partner Ackman thinks so. Story | Follow @CarlyHFierce
> FDA staffers raise doubts over key Vertex combo. Item
> AdverseEvents: New generation of hep C meds bests older therapies in side-effect reports. More
> Amarin sues FDA over 'free speech' issue the agency says it is ready to hash out. Article